United States - English - NLM (National Library of Medicine)

janssen biotech, inc. - abciximab (unii: x85g7936gv) (abciximab - unii:x85g7936gv) - abciximab 2 mg in 1 ml - abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications - in patients undergoing percutaneous coronary intervention - in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours safety and efficacy of abciximab use in patients not undergoing percutaneous coronary intervention have not been established. abciximab is intended for use with aspirin and heparin and has been studied only in that setting, as described in clinical studies. because abciximab may increase the risk of bleeding, abciximab is contraindicated in the following clinical situations: - active internal bleeding - recent (within six weeks) gastrointestinal (gi) or genitourinary (gu) bleeding of clinical significance - history of cerebrovascular accident (cva) within two years, or cva with a significant residual neurological deficit - bleeding diathesis - administration of oral anticoagulan

United States - English - NLM (National Library of Medicine)

eli lilly and company - abciximab (unii: x85g7936gv) (abciximab - unii:x85g7936gv) - abciximab 2 mg in 1 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - abciximab -

Canada - English - Health Canada

janssen inc - abciximab - solution - 2mg - abciximab 2mg - miscellaneous therapeutic agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - abciximab - solution for injection - 2mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

janssen biologics b.v. - abciximab - solution for inj/inf - 2 mg/ml - platelet aggregation inhibitors excl. heparin

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - abciximab 2 mg/ml - solution for injection - 2 mg/ml - active: abciximab 2 mg/ml excipient: dibasic sodium phosphate dihydrate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - reopro is indicated as an adjunct to heparin and aspirin for: percutaneous coronary intervention: the prevention of ischaemic cardiac complications (death, myocardial infarction or need for urgent intervention) in patients during or following percutaneous coronary intervention (balloon angioplasty, atherectomy and stent placement).

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - abciximab -

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة الشرق الاوسط للصناعات الدوائية - middle east pharmaceutical and chemical industries - abciximab 10 mg/5ml - 10 mg/5ml

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

janssen biologics b.v. - abciximab 2 mg/ml - solution for injection/infusion - abciximab